Invesco Pharmaceuticals ETF

PJP

Market cap $264M

Overview Fund Activity

92.00 USD

-1.64

1.75%

At close Updated Sep 12, 4:00 PM EDT

1 day

-1.75%

5 days

0.45%

1 month

4.9%

3 months

11.98%

6 months

8.88%

Year to date

10.84%

1 year

6.49%

5 years

42.22%

10 years

21.87%

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.53% less ownership

Funds ownership: 22.82% [Q1] → 22.29% (-0.53%) [Q2]

4% less funds holding

Funds holding: 96 [Q1] → 92 (-4) [Q2]

13% less capital invested

Capital invested by funds: $59.6M [Q1] → $51.8M (-$7.72M) [Q2]

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

32% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 28

See Fund Rankings

Financial journalist opinion

Based on 3 articles about PJP published over the past 30 days

Zacks Investment Research

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund launched on 06/23/2005.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

PJP: Healthcare Dashboard For August

This article provides a top-down view of the healthcare sector based on valuation, quality and momentum. The healthcare providers and pharmaceuticals/biotechnology subsectors show good value scores. The Invesco Pharmaceuticals ETF has outperformed the pharma industry benchmark XPH and the broader healthcare ETF XLV since 2006.

PJP: Healthcare Dashboard For August

Zacks Investment Research

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the Invesco Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on 06/23/2005.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Healthcare Sector Checkup As U.S. Looks To Change Regulations

PJP: The Pharma Executive Order May Be Inconsequential

President Trump's executive order on drug pricing caused a surprising rally in pharmaceutical stocks, despite initial fears of negative impacts on profit margins. The order lacks enforcement mechanisms, making it difficult to implement, which may explain the positive market reaction. Distributors like McKesson and Cardinal Health were negatively impacted, while manufacturers in the PJP ETF saw gains.

PJP: The Pharma Executive Order May Be Inconsequential

Zacks Investment Research

ETFs on the Move Post U.S.-China Trade Deal

Let's delve into the ETF world following the 90-day U.S.-China trade deal.

ETFs on the Move Post U.S.-China Trade Deal

Zacks Investment Research

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Launched on 06/23/2005, the Invesco Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Zacks Investment Research

A Look at Pharma ETFs After Strong Q1 Earnings

Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Strong Q1 Earnings

See News Rankings

Charts implemented using Lightweight Charts™